Evidence map›Paper›PMID 25898689›Full record

ReviewJournal of investigational allergology & clinical immunology2015

Group 2 innate lymphoid cells: new players in human allergic diseases.

T A Doherty, D H Broide

Abstract readReview
In one paragraph

Review in Journal of investigational allergology & clinical immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 44 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Chronic Rhinosinusitis,Biomedicines · 2022
    Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Asthma biologics: Comparing trial designs, patient cohorts and study results.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2020
    Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Airway innate lymphoid cells in the induction and regulation of allergy.Allergology international : official journal of the Japanese Society of Allergology · 2019
    Review
  16. Article
  17. Article
  18. Review
  19. βThe Journal of allergy and clinical immunology · 2018
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

T A Doherty
D H Broide

Funding

TRM and airway inflammation and remodelingU19AI070535 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BROIDE, DAVID H · 2006 to 2025
$34.2M
Chromosome 17q, allergic inflammation, and remodelingR01AI107779 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BROIDE, DAVID H · 2013 to 2024
$4.7M
Eosinophil trafficking and chronic tissue damage induced by allergic inflammationR37AI038425 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BROIDE, DAVID H · 2007 to 2016
$3.7M
RBM3 regulation of type 2 innate lymphoid cells in allergic inflammationR01AI114585 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DOHERTY, TAYLOR A · 2015 to 2019
$2.3M
Eosinophil TraffickingR01AI038425 · NIAID · UNIVERSITY OF CALIFORNIA SAN DIEGO · PI BROIDE, DAVID H · 1996 to 2005
$1.8M
Siglec-F and Resolution of Allergic InflammationR01AI072115 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BROIDE, DAVID H · 2008 to 2012
$1.7M
OX40/OX40L interactions in allergen-induced airway inflammation and remodelingK08AI080938 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DOHERTY, TAYLOR A · 2010 to 2014
$662k
NIAID NIH HHS AI 72115NIAID NIH HHS K08 AI080938NIAID NIH HHS K08AI080938NIAID NIH HHS R01 AI038425NIAID NIH HHS R01 AI072115NIAID NIH HHS R01 AI107779NIAID NIH HHS R01 AI114585NIAID NIH HHS R01AI114585NIAID NIH HHS R37 AI038425NIAID NIH HHS U19 AI070535
6 · The paper itself

Abstract

Allergic diseases are characterized by tissue eosinophilia, mucus secretion, IgE production, and activation of mast cells and TH2 cells. Production of TH2 cytokines including IL-4, IL-5, IL-9, and IL-13 has mainly been attributed to CD4+T(H)2 cells. However, the recent discovery of group 2 innate lymphoid cells (ILC2s) in humans and findings from experimental disease models have challenged conventional concepts associated with the contribution of specific cells to type 2 inflammation in allergic diseases. ILC2s produce high levels of T(H)2 cytokines and have been detected in human lung tissue, peripheral blood, the gastrointestinal tract, skin, and sinonasal tissue, suggesting that ILC2s could contribute to chronic rhinosinusitis, asthma, atopic dermatitis, and gastrointestinal allergic disease. Moreover, depletion of ILC2s in animal models suggests a role for these cells in atopic dermatitis and asthma. This review will focus on the role of ILC2s in human allergy and asthma and provide a mechanistic insight from animal models.

Indexed as

AnimalsHumansHypersensitivityLymphocytesPneumoniaSkin Diseases

Identifiers

PMID25898689
PMCPMC4545833
OpenAlexW2188513396

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.